BeiGene, Ltd. - American Depositary Shares (NQ:BGNE)

184.71 UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 31, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BeiGene, Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting

April 24, 2024

From BeiGene, Ltd.

Via Business Wire

Evaluating BeiGene: Insights From 6 Financial Analysts ↗

April 24, 2024

Via Benzinga

HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday ↗

April 23, 2024

Via Benzinga

BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

April 23, 2024

From BeiGene, Ltd.

Via Business Wire

4 Analysts Assess BeiGene: What You Need To Know ↗

March 27, 2024

Via Benzinga

BeiGene Ltd. (NASDAQ: BGNE) is a Leading Gainer in 3/13 Morning Trading

March 13, 2024

Via Investor Brand Network

Week In Review: AriBio Sells China Rights To Alzheimer’s Candidate In $770 Million Deal ↗

March 30, 2024

South Korea’s AriBio out-licensed China rights for AR1001, an Alzheimer’s disease candidate, in an agreement worth up to $770 million. The company acquiring the asset asked to remain anonymous because...

Via Talk Markets

Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities ↗

March 23, 2024

Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility.

Via Talk Markets

Lululemon Issues Weak Outlook, Joins Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

March 22, 2024

U.S. stock futures were higher this morning, with the Dow futures gaining by around 0.1% on Friday.

Via Benzinga

Topics Stocks

FDA Approves BeiGene's First Drug Candidate Produced Through Its Immuno-Oncology Program For Esophageal Cancer ↗

March 15, 2024

FDA approves BeiGene's Tevimbra for esophageal squamous cell carcinoma, offering hope for patients after prior chemotherapy. Tevimbra's efficacy was demonstrated in the RATIONALE 302 trial with...

Via Benzinga

BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

March 14, 2024

From BeiGene, Ltd.

Via Business Wire

Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

March 13, 2024

Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24...

Via Benzinga

First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation

March 13, 2024

From BeiGene

Via Business Wire

Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session ↗

March 13, 2024

U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday.

Via Benzinga

FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer ↗

March 08, 2024

FDA grants accelerated approval to BeiGene's Brukinsa for relapsed/refractory follicular lymphoma. Approved in combination with Roche's Gazyva after two or more lines of therapy. Brukinsa, priced at...

Via Benzinga

BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma

March 07, 2024

From BeiGene, Ltd.

Via Business Wire

BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024

March 06, 2024

From BeiGene, Ltd.

Via Business Wire

BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

February 29, 2024

From BeiGene, Ltd.

Via Business Wire

BeiGene to Present at Upcoming Investor Conferences

February 28, 2024

From BeiGene, Ltd.

Via Business Wire

BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA

February 27, 2024

From BeiGene, Ltd.

Via Business Wire

BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

February 26, 2024

From BeiGene, Ltd.

Via Business Wire

BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

February 26, 2024

From BeiGene, Ltd.

Via Business Wire

Hang Seng Index Set For Global Expansion With Prada, XPeng, And BeiGene On The Horizon ↗

February 16, 2024

This development comes at a time when the city is grappling with a declining market.

Via Benzinga

Get Rich Quick With These 3 Biotech Stocks to Buy Now ↗

February 13, 2024

The new cycle is coming your way to boost millionaire-making securities. Check out these three biotech stocks to buy.

Via InvestorPlace

3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List ↗

February 06, 2024

These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry.

Via InvestorPlace

JP Morgan's Bullish View On This Chinese Biotech, Says Pullback Creates Entry Point ↗

February 06, 2024

BeiGene's JP Morgan coverage highlights upside in valuation post-pullback. Brukinsa's success and Tevimbra's potential add to the optimism. Overweight rating, $185 price target.

Via Benzinga

BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors

January 23, 2024

From BeiGene, Ltd.

Via Business Wire

5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond ↗

January 15, 2024

These five biotech companies could have a lot of room to run.

Via The Motley Fool

As China's Population Declines In 2023, Will Aging Demographics Boost Healthcare Stocks? ↗

January 10, 2024

Exploring the economic implications of China's declining population on property markets and the potential rise of healthcare and tech investments.

Via Benzinga

3 Top Biotech Stocks Worth Adding To Your Portfolio In 2024 ↗

January 07, 2024

Given the continuous need for innovative medical treatments, the biotech industry may be a haven despite its inherent volatility and an uncertain macroeconomic environment. Here are three top biotech...

Via Talk Markets

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.